COL-3 acute treatment attenuated LID once dyskinesia was present
L-DOPA-treated lesioned rats were administered an i.c.v. microinjection of COL-3 at two different doses (50 or 100 nmol, 10 minutes before L-DOPA) over 10 days. A dose of 100 nmol of COL-3 was found to significantly reduce L-DOPA induced dyskinesia (6-OHDA+vehicle+L-DOPA, AIMs sum 47.93±7.93; lesion+COL-3+L-DOPA, AIMs sum 20.57±3.70; p< 0.01; Fig. 5-A; p <0.05). COL-3 reduced dyskinesia over a 20 to 140 min period, as observed in the time response curve (Fig. 5-B). No significant differences were found with 50 nmol of COL-3 (6-OHDA+COL-3+L-DOPA: 42±5.72). Moreover, COL-3 administration reduced axial, limb, and orofacial dyskinesia (p<0.0001; Supplementary Figs. 2-G, -H and -I).
COL-3 treatment (100 nmol) did not affect the L-DOPA improvements in the locomotor outcomes as measured by the distance traveled and time immobile (Supplementary, Table 1).